leflunomide has been researched along with Cytomegalovirus Infections in 32 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Cytomegalovirus Infections: Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data concerning the use of leflunomide-a drug approved for rheumatoid arthritis with in vitro anticytomegalovirus (CMV) activity-in lung transplant (LT) recipients are scarce." | 8.98 | Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature. ( Aguado, JM; Alonso-Moralejo, R; Brañas, P; de Pablo-Gafas, A; Fernández-Ruiz, M; Folgueira, MD; Lopez-Medrano, F; Pérez-González, V; San-Juan, R; Silva, JT, 2018) |
| "The primary objective of this case series was to determine the clinical and virological responses of utilizing leflunomide as therapy for refractory cytomegalovirus infections, unresponsive to first-line therapy in allogeneic stem cell transplant patients." | 7.91 | Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients. ( Doan, VP; Ferguson, JB; Jan, AS; Wang, E; Yeh, JC, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 7.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Leflunomide, a disease-modifying antirheumatic drug (DMARD), has shown effectiveness in many autoimmune disorders and can suppress cytomegalovirus (CMV) disease in humans." | 7.81 | Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects? ( Hsieh, SC; Lu, CH; Tsai, JH; Wu, MZ; Yu, CL, 2015) |
| "The immunomodulatory drug leflunomide (LEF) is frequently used for treating human cytomegalovirus (HCMV), but its antiviral mechanism is still unclear." | 7.79 | Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus. ( Hua-Song, Z; Qi, R; Xiao-Feng, Z, 2013) |
| "Leflunomide has been shown to have immunosuppressive activity in experimental allograft models together with antiviral activity inhibiting CMV both in vitro and in vivo." | 6.77 | Leflunomide for cytomegalovirus: bench to bedside. ( Chacko, B; John, GT, 2012) |
| "Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking." | 5.43 | Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. ( Ariza-Heredia, E; Chemaly, RF; Doan, V; El Chaer, F; Jan, A; Mori, N; Oliver, N; Shah, D; Tayar, J; Tverdek, F; Wang, E, 2016) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 5.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| "Data concerning the use of leflunomide-a drug approved for rheumatoid arthritis with in vitro anticytomegalovirus (CMV) activity-in lung transplant (LT) recipients are scarce." | 4.98 | Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature. ( Aguado, JM; Alonso-Moralejo, R; Brañas, P; de Pablo-Gafas, A; Fernández-Ruiz, M; Folgueira, MD; Lopez-Medrano, F; Pérez-González, V; San-Juan, R; Silva, JT, 2018) |
| "The primary objective of this case series was to determine the clinical and virological responses of utilizing leflunomide as therapy for refractory cytomegalovirus infections, unresponsive to first-line therapy in allogeneic stem cell transplant patients." | 3.91 | Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients. ( Doan, VP; Ferguson, JB; Jan, AS; Wang, E; Yeh, JC, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 3.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Leflunomide, a disease-modifying antirheumatic drug (DMARD), has shown effectiveness in many autoimmune disorders and can suppress cytomegalovirus (CMV) disease in humans." | 3.81 | Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects? ( Hsieh, SC; Lu, CH; Tsai, JH; Wu, MZ; Yu, CL, 2015) |
| "The immunomodulatory drug leflunomide (LEF) is frequently used for treating human cytomegalovirus (HCMV), but its antiviral mechanism is still unclear." | 3.79 | Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus. ( Hua-Song, Z; Qi, R; Xiao-Feng, Z, 2013) |
| "We previously reported that the immunosuppressive malononitrileamides leflunomide and FK778 exert antiviral activity against cytomegalovirus (CMV)." | 3.73 | Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. ( Chong, AS; Knight, DA; Meister, GT; Shen, J; Waldman, WJ; Williams, JW; Zeng, H, 2006) |
| "Leflunomide has been shown to have immunosuppressive activity in experimental allograft models together with antiviral activity inhibiting CMV both in vitro and in vivo." | 2.77 | Leflunomide for cytomegalovirus: bench to bedside. ( Chacko, B; John, GT, 2012) |
| "Leflunomide treatment for CMV disease in renal transplant recipients is effective, simple, and economical." | 2.71 | A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. ( Balakrishnan, N; Chandy, S; Chandy, SJ; Fleming, DH; Jacob, CK; John, GT; Kirubakaran, MG; Krishnamurthy, K; Manivannan, J; Peter, S, 2005) |
| "Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking." | 1.43 | Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. ( Ariza-Heredia, E; Chemaly, RF; Doan, V; El Chaer, F; Jan, A; Mori, N; Oliver, N; Shah, D; Tayar, J; Tverdek, F; Wang, E, 2016) |
| "Treatment with leflunomide is a reasonable option in ganciclovir-resistant infection in kidney transplant recipients, providing effective viral elimination and reconstitution of adaptive anti-CMV immunity without excess risk of graft rejection." | 1.40 | Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report. ( Chmura, A; Ciszek, M; Foroncewicz, B; Mucha, K; Pączek, L, 2014) |
| "Leflunomide was initiated after a median of three episodes of CMV viremia, with a mean peak viral load of 245,826 copies/mL." | 1.36 | Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. ( Avery, RK; Bolwell, B; Braun, W; Budev, M; Fatica, R; Krishnamurthi, V; Lard, M; Lurain, N; Mawhorter, SD; Mossad, SB; Poggio, E; Shrestha, R; Stephany, B; Waldman, WJ; Yen-Lieberman, B; Young, JB, 2010) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 1.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| "Leflunomide has excellent antiviral activity against cytomegalovirus (CMV) in animal models and is considerably less expensive than intravenous ganciclovir." | 1.32 | Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. ( Chandy, S; Jacob, CK; John, GT; Manivannan, J; Peter, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 22 (68.75) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Santhanakrishnan, K | 1 |
| Yonan, N | 1 |
| Iyer, K | 1 |
| Callan, P | 1 |
| Al-Aloul, M | 1 |
| Venkateswaran, R | 1 |
| Echenique, IA | 1 |
| Beltran, D | 1 |
| Ramirez-Ruiz, L | 1 |
| Najafian, N | 1 |
| Agrawal, N | 1 |
| Silva, JT | 1 |
| Pérez-González, V | 1 |
| Lopez-Medrano, F | 1 |
| Alonso-Moralejo, R | 1 |
| Fernández-Ruiz, M | 1 |
| San-Juan, R | 1 |
| Brañas, P | 1 |
| Folgueira, MD | 1 |
| Aguado, JM | 1 |
| de Pablo-Gafas, A | 1 |
| Wang, E | 2 |
| Jan, AS | 1 |
| Doan, VP | 1 |
| Ferguson, JB | 1 |
| Yeh, JC | 1 |
| Verkaik, NJ | 1 |
| Hoek, RA | 1 |
| van Bergeijk, H | 1 |
| van Hal, PT | 1 |
| Schipper, ME | 1 |
| Pas, SD | 1 |
| Beersma, MF | 1 |
| Boucher, CA | 1 |
| Jedema, I | 1 |
| Falkenburg, F | 1 |
| Hoogsteden, HC | 1 |
| van den Blink, B | 1 |
| Murk, JL | 1 |
| Ciszek, M | 1 |
| Mucha, K | 1 |
| Foroncewicz, B | 1 |
| Chmura, A | 1 |
| Pączek, L | 1 |
| Lu, CH | 1 |
| Tsai, JH | 1 |
| Wu, MZ | 1 |
| Yu, CL | 1 |
| Hsieh, SC | 1 |
| Kneidinger, N | 1 |
| Giessen, C | 1 |
| von Wulffen, W | 1 |
| Milger, K | 1 |
| Schramm, R | 1 |
| Jäger, G | 1 |
| Nitschko, H | 1 |
| Striebinger, H | 1 |
| Behr, J | 1 |
| Neurohr, C | 1 |
| Boeckh, M | 1 |
| Murphy, WJ | 1 |
| Peggs, KS | 1 |
| Miszewska-Szyszkowska, D | 1 |
| Mikołajczyk, N | 1 |
| Komuda-Leszek, E | 1 |
| Wieczorek-Godlewska, R | 1 |
| Świder, R | 1 |
| Dęborska-Materkowska, D | 1 |
| Szmidt, J | 1 |
| Durlik, M | 1 |
| Gagneux-Brunon, A | 1 |
| Pillet, S | 1 |
| Laurent, B | 1 |
| Mariat, C | 1 |
| Michalet, M | 1 |
| Lucht, F | 1 |
| Botelho-Nevers, E | 1 |
| Gómez Valbuena, I | 1 |
| Alioto, D | 1 |
| Serrano Garrote, O | 1 |
| Ferrari Piquero, JM | 1 |
| Ambrose, T | 1 |
| Sharkey, LM | 1 |
| Louis-Auguste, J | 1 |
| Rutter, CS | 1 |
| Duncan, S | 1 |
| English, S | 1 |
| Gkrania-Klotsas, E | 1 |
| Carmichael, A | 2 |
| Woodward, JM | 1 |
| Russell, N | 1 |
| Massey, D | 1 |
| Butler, A | 1 |
| Middleton, S | 1 |
| Morita, S | 1 |
| Shinoda, K | 1 |
| Tamaki, S | 1 |
| Kono, H | 1 |
| Asanuma, H | 1 |
| Nakagawa, K | 1 |
| Oya, M | 1 |
| El Chaer, F | 1 |
| Mori, N | 1 |
| Shah, D | 1 |
| Oliver, N | 1 |
| Jan, A | 1 |
| Doan, V | 1 |
| Tverdek, F | 1 |
| Tayar, J | 1 |
| Ariza-Heredia, E | 1 |
| Chemaly, RF | 1 |
| Bright, PD | 1 |
| Gompels, M | 1 |
| Donati, M | 1 |
| Johnston, S | 1 |
| Snydman, DR | 1 |
| Avery, RK | 3 |
| Mossad, SB | 3 |
| Poggio, E | 1 |
| Lard, M | 1 |
| Budev, M | 1 |
| Bolwell, B | 1 |
| Waldman, WJ | 5 |
| Braun, W | 1 |
| Mawhorter, SD | 1 |
| Fatica, R | 1 |
| Krishnamurthi, V | 1 |
| Young, JB | 1 |
| Shrestha, R | 1 |
| Stephany, B | 1 |
| Lurain, N | 2 |
| Yen-Lieberman, B | 2 |
| Teschner, S | 1 |
| Burst, V | 1 |
| Orden, AO | 1 |
| Chuluyan, JC | 1 |
| Colombini, AC | 1 |
| Barbera, RF | 1 |
| Chacko, B | 1 |
| John, GT | 4 |
| Goldsmith, PM | 1 |
| Husain, MM | 1 |
| Zhang, H | 1 |
| Middleton, SJ | 1 |
| Qi, R | 1 |
| Hua-Song, Z | 1 |
| Xiao-Feng, Z | 1 |
| Manivannan, J | 2 |
| Chandy, S | 2 |
| Peter, S | 2 |
| Jacob, CK | 2 |
| Bolwell, BJ | 1 |
| Longworth, DL | 1 |
| Taege, AJ | 1 |
| Kohn, D | 1 |
| Long, JR | 1 |
| Curtis, J | 1 |
| Kalaycio, M | 1 |
| Pohlman, B | 1 |
| Williams, JW | 4 |
| Fleming, DH | 1 |
| Chandy, SJ | 1 |
| Balakrishnan, N | 1 |
| Krishnamurthy, K | 1 |
| Kirubakaran, MG | 1 |
| Chong, AS | 3 |
| Zeng, H | 1 |
| Knight, DA | 3 |
| Shen, J | 2 |
| Meister, GT | 1 |
| Sudarsanam, TD | 1 |
| Sahni, RD | 1 |
| Battiwalla, M | 1 |
| Paplham, P | 1 |
| Almyroudis, NG | 1 |
| McCarthy, A | 1 |
| Abdelhalim, A | 1 |
| Elefante, A | 1 |
| Smith, P | 1 |
| Becker, J | 1 |
| McCarthy, PL | 1 |
| Segal, BH | 1 |
| Lurain, NS | 2 |
| Miller, DM | 2 |
| Sedmak, DD | 2 |
| Blinder, L | 1 |
8 reviews available for leflunomide and Cytomegalovirus Infections
| Article | Year |
|---|---|
Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; | 2022 |
Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature.
Topics: Adult; Aged; Cytomegalovirus; Cytomegalovirus Infections; Female; Follow-Up Studies; Humans; Immunos | 2018 |
Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, | 2013 |
Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.
Topics: Acetates; Adoptive Transfer; Animals; Antiviral Agents; Benzimidazoles; Cell- and Tissue-Based Thera | 2015 |
Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with high-level antigenemia in a kidney transplant: A case report and literature review.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Ganciclovir; Humans; I | 2016 |
Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review.
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Blood; Cytomegalovirus; Cytomegalovirus Infe | 2017 |
Leflunomide: a drug with a potential beyond rheumatology.
Topics: Animals; Antirheumatic Agents; Biological Availability; Contraindications; Cytomegalovirus Infection | 2010 |
Leflunomide: a possible alternative for gangciclovir sensitive and resistant cytomegalovirus infections.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infections; Drug Resistance, Vi | 2006 |
2 trials available for leflunomide and Cytomegalovirus Infections
| Article | Year |
|---|---|
Leflunomide for cytomegalovirus: bench to bedside.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Humans; Isoxazoles; Leflunomide; Tran | 2012 |
A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Humans; Isoxazoles; Kidney Transplantat | 2005 |
22 other studies available for leflunomide and Cytomegalovirus Infections
| Article | Year |
|---|---|
Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Dose-Respo | 2017 |
Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients.
Topics: Adult; Aged; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; DNA, Viral; Female; Genotype; | 2019 |
Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; Graft Rejection; | 2014 |
Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects?
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dr | 2015 |
Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet; Ganc | 2014 |
Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-or
Topics: Adult; Antiviral Agents; Cholangitis; Cytomegalovirus Infections; Diabetes Mellitus, Type 2; Fatal O | 2015 |
A case of BK virus nephropathy in a stem cell transplant recipient: a rare or under-recognized cause for Acute Kidney injury.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; BK Virus; Ciprofloxacin; Cord Blood Stem Cell Transplant | 2015 |
[Use of leflunomide in a cytomegalovirus infection resistant: a report of a case].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Human | 2016 |
Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet | 2016 |
Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
Topics: Aged; Antiviral Agents; Chemotherapy, Adjuvant; Cytomegalovirus; Cytomegalovirus Infections; Drug Mo | 2016 |
Leflunomide: a small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection.
Topics: Algorithms; Antiviral Agents; Benzimidazoles; Cytomegalovirus Infections; Drug Resistance, Viral; Ga | 2010 |
Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.
Topics: Antiviral Agents; Cytomegalovirus Infections; Ganciclovir; Heart Transplantation; Humans; Immunosupp | 2010 |
Leflunomide use in a cytomegalovirus infection of a patient with dermatomyositis.
Topics: Antirheumatic Agents; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dermatomyositis | 2012 |
Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2012 |
Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus.
Topics: Apoptosis; Cell Proliferation; Cell Shape; Cytomegalovirus; Cytomegalovirus Infections; Embryo, Mamm | 2013 |
Leflunomide therapy for cytomegalovirus disease in renal allograft recepients.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Costs; Female; Humans; India; Isoxazoles; | 2004 |
Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
Topics: Bone Marrow Transplantation; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, Combi | 2004 |
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
Topics: Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Graft Rejection; Heart; Hear | 2006 |
Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Therapy, Co | 2007 |
Second look at leflunomide "failure" to control cytomegalovirus infection in the setting of renal failure.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Humans; Isoxazoles; Leflunomide; Rena | 2007 |
Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.
Topics: Antiviral Agents; Blotting, Northern; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA | 1999 |
Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide.
Topics: Animals; Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; | 1999 |